Antiviral therapeutics for chikungunya virus

References

• Burt FJ, Chen W, Miner JJ, et al. Chikungunya virus: an update on the biology and pathogenesis of this emerging pathogen. Lancet Infect Dis. 2017;17(4):e107–17.
   PubMed Web of Science ®Google Scholar
• Cunha RVD, Trinta KS. Chikungunya virus: clinical aspects and treatment-A review. Mem Inst Oswaldo Cruz. 2017;112(8):523–531.
   PubMed Web of Science ®Google Scholar
• Carissimo G, Ng LFP. Understanding molecular pathogenesis with chikungunya virus research tools. Curr Top Microbiol Immunol. 2019. DOI:10.1007/82_2019_158
   PubMedGoogle Scholar
• Moizéis RN, Fernandes TAA, Guedes PM, et al. Chikungunya fever: a threat to global public health. Pathog Glob Health. 2018;112(4):182–194.
   PubMed Web of Science ®Google Scholar
• Wimalasiri-Yapa BR, Stassen L, Huang X, et al. Chikungunya virus in Asia–Pacific: A systematic review. Emerg Microbes Infect. 2019;8(1):70–79.
   PubMed Web of Science ®Google Scholar
• Ganesan VK, Duan B, Reid SP. Chikungunya virus: Pathophysiology, mechanism, and modeling. Viruses. 2017;9(12):368.
   Google Scholar
• Chompoosri J, Thavara U, Tawatsin A, et al. Vertical transmission of Indian Ocean lineage of chikungunya virus in aedes aegypti and aedes albopictus mosquitoes. Parasit Vectors. 2016;9(1):227.
   PubMedGoogle Scholar
• Alto BW, Wiggins K, Eastmond B, et al. Transmission risk of two chikungunya lineages by invasive mosquito vectors from florida and the dominican republic. PLoS Negl Trop Dis. 2017;11(7):e0005724.
   PubMed Web of Science ®Google Scholar
• Coffey LL, Failloux AB, Weaver SC. Chikungunya virus–vector interactions. Viruses. 2014;6(11):4628–4663.
   PubMed Web of Science ®Google Scholar
• Hoornweg TE, van Duijl-richter MK, Nuñez NV, et al. Dynamics of chikungunya virus cell entry unraveled by single-virus tracking in living cells. J Virol. 2016;90(9):4745–4756.
   PubMed Web of Science ®Google Scholar
• Gao Y, Goonawardane N, Ward J, et al. Multiple roles of the non-structural protein 3 (nsP3) alphavirus unique domain (AUD) during Chikungunya virus genome replication and transcription. PLoS Pathog. 2019;15(1):e1007239.
   PubMed Web of Science ®Google Scholar
• Stelitano D, Chianese A, Astorri R, et al. Chikungunya virus: update on molecular biology, epidemiology and current strategies.Transl Med Rep; 2019; 3: 1.
   Google Scholar
• Barr KL, Vaidhyanathan V. Chikungunya in infants and children: is pathogenesis increasing? Viruses. 2019;11(3):294.
   Web of Science ®Google Scholar
• Goodman AG, Rasmussen AL. Host-pathogen interactions during arboviral infections. Front Cell Infect Microbiol. 2019;9:77.
   PubMed Web of Science ®Google Scholar
• Michlmayr D, Pak TR, Rahman AH, et al. Comprehensive innate immune profiling of chikungunya virus infection in pediatric cases. Mol Syst Biol. 2018;14(8):e7862.
   PubMed Web of Science ®Google Scholar
• Subudhi BB, Chattopadhyay S, Mishra P. Current strategies for inhibition of chikungunya infection. Viruses. 2018;10(5):235.
   PubMed Web of Science ®Google Scholar
• Tharmarajah K, Mahalingam S, Zaid A. Chikungunya : vaccines and therapeutics. F1000 Res. 2017;6:2114.
   PubMedGoogle Scholar
• Wong KZ, Chu JJ. The interplay of viral and host factors in chikungunya virus infection: targets for antiviral strategies. Viruses. 2018;10(6):294.
   Web of Science ®Google Scholar
• Kim S, Chen J, Cheng T, et al. PubChem 2019 update: improved access to chemical data. Nucleic Acids Res. 2019;47(D1):D1102–9.
   PubMed Web of Science ®Google Scholar
• CSID:2618. Cited 2020 Mar 19. Available from: http://www.chemspider.com/Chemical-Structure.2618.html
   Google Scholar
• da Silva-júnior EF, Leoncini GO, ÉES R, et al. The medicinal chemistry of Chikungunya virus. Bioorg Med Chem. 2017;25(16):4219–4244.
   PubMed Web of Science ®Google Scholar
• Sales GMPG, Barbosa ICP, LMS CN, et al. Treatment of chikungunya chronic arthritis. Rev Assoc Med Bras. 2018;64(1):63–70.
   PubMed Web of Science ®Google Scholar
• Rothan HA, Bahrani H, Mohamed Z, et al. A combination of doxycycline and ribavirin alleviated chikungunya infection. PLoS One. 2015;10(5):e0126360.
   PubMed Web of Science ®Google Scholar
• Delang L, Segura Guerrero N, Tas A, et al. Mutations in the Chikungunya virus non-structural proteins cause resistance to favipiravir (T-705), a broad-spectrum antiviral. J Antimicrob Chemother. 2014;69(10):2770–2784.
   PubMed Web of Science ®Google Scholar
• Huchting J, Vanderlinden E, Van Berwaer R, et al. Cell line-dependent activation and antiviral activity of T-1105, the non-fluorinated analogue of T-705 (favipiravir). Antiviral Res. 2019;167:1–5.
   PubMed Web of Science ®Google Scholar
• Khan M, Santhosh SR, Tiwari M, et al. Assessment of in vitro prophylactic and therapeutic efficacy of chloroquine against Chikungunya virus in vero cells. J Med Virol. 2010;82(5):817–824.
   PubMed Web of Science ®Google Scholar
• Roques P, Thiberville SD, Dupuis-Maguiraga L, et al. Paradoxical effect of chloroquine treatment in enhancing chikungunya virus infection. Viruses. 2018;10(5):268.
   PubMed Web of Science ®Google Scholar
• Delogu I, Pastorino B, Baronti C, et al. In vitro antiviral activity of arbidol against Chikungunya virus and characteristics of a selected resistant mutant. Antiviral Res. 2011;90(3):99–107.
   PubMed Web of Science ®Google Scholar
• Marra RK, Kümmerle AE, Guedes GP, et al. Quinolone-N-acylhydrazone hybrids as potent Zika and Chikungunya virus inhibitors. Bioorg Med Chem Lett. 2020;30(2):126881.
   PubMed Web of Science ®Google Scholar
• Briolant S, Garin D, Scaramozzino N, et al. In vitro inhibition of Chikungunya and semliki forest viruses replication by antiviral compounds: Synergistic effect of interferon-α and ribavirin combination. Antiviral Res. 2004;61(2):111–117.
   PubMed Web of Science ®Google Scholar
• Ho YJ, Wang YM, Lu JW, et al. Suramin inhibits chikungunya virus entry and transmission. PloS One. 2015;10(7):e0133511.
   PubMed Web of Science ®Google Scholar
• Delang L, Li C, Tas A, et al. The viral capping enzyme nsP1: a novel target for the inhibition of chikungunya virus infection. Sci Rep. 2016;6:31819.
   PubMed Web of Science ®Google Scholar
• Haese N, Powers J, Streblow DN. Small molecule inhibitors targeting chikungunya virus. Curr Top Microbiol Immunol. 2020.DOI:10.1007/82_2020_195[published online ahead of print]
   PubMedGoogle Scholar
• Ghildiyal R, Gupta S, Gabrani R, et al. In silico study of Chikungunya polymerase, a potential target for inhibitors. Virus Dis. 2019;30(3):394–402.
   Google Scholar
• Hwu JR, Huang WC, Lin SY, et al. Chikungunya virus inhibition by synthetic coumarin e guanosine conjugates. Eur J Med Chem. 2019;166:136–143.
   PubMed Web of Science ®Google Scholar
• Morrison CR, Plante KS, Heise MT. Chikungunya virus: Current perspectives on a reemerging virus. Microbiol Spectr. 2016;4:3.
   Web of Science ®Google Scholar
• Puranik NV, Rani R, Singh VA, et al. Evaluation of the Antiviral Potential of Halogenated Dihydrorugosaflavonoids and Molecular Modeling with nsP3 Protein of Chikungunya Virus (CHIKV). ACS Omega. 2019;4(23):20335–20345.
   PubMed Web of Science ®Google Scholar
• Xu J, Xu Z, Zheng W. A review of the antiviral role of green tea catechins. Molecules. 2017;22(8): 1337.
   Google Scholar
• Weber C, Sliva K, Von Rhein C, et al. The green tea catechin, epigallocatechin gallate inhibits chikungunya virus infection. Antiviral Res. 2015;113:1–3.
   PubMed Web of Science ®Google Scholar
• Lu JW, Hsieh PS, Lin CC, et al., Synergistic effects of combination treatment using EGCG and suramin against the chikungunya virus. Biochem Biophys Res Commun. 2017;491(3): 595–602.
   PubMed Web of Science ®Google Scholar
• Henss L, Scholz T, Grünweller A, et al. Silvestrol inhibits chikungunya virus replication. Viruses. 2018;10(11):592.
   Web of Science ®Google Scholar
• Varghese FS, Thaa B, Amrun SN, et al. The antiviral alkaloid berberine reduces chikungunya virus-induced. J Virol. 2016;90(21):9743–9757.
   PubMed Web of Science ®Google Scholar
• Corlay N, Delang L, Girard-Valenciennes E, et al. Tigliane diterpenes from Croton mauritianus as inhibitors of chikungunya virus replication. Fitoterapia. 2014;97:87–91.
   PubMed Web of Science ®Google Scholar
• Oliveira AF, Teixeira RR, Oliveira AS, et al. Potential antivirals: natural products targeting replication enzymes of dengue and Chikungunya viruses. Molecules. 2017;22(3):505.
   Web of Science ®Google Scholar
• Esposito M, Nothias LF, Retailleau P, et al. Isolation of premyrsinane, myrsinane, and tigliane diterpenoids from euphorbia pithyusa using a chikungunya virus cell-based assay and analogue annotation by molecular networking. J Nat Prod. 2017;80(7):2051–2059.
   PubMed Web of Science ®Google Scholar
• Lani R, Hassandarvish P, Shu MH, et al. Antiviral activity of selected flavonoids against Chikungunya virus. Antiviral Res. 2016;133:50–61.
   PubMed Web of Science ®Google Scholar
• Ahmadi A, Hassandarvish P, Lani R, et al. Inhibition of chikungunya virus replication by hesperetin and naringenin. RSC Adv. 2016;6(73):69421–69430.
   Web of Science ®Google Scholar
• Vora J, Patel S, Sinha S, et al. Structure based virtual screening, 3D-QSAR, molecular dynamics and ADMET studies for selection of natural inhibitors against structural and non-structural targets of Chikungunya. J Biomol Struct Dyn. 2019;37(12):3150–3161.
   PubMed Web of Science ®Google Scholar
• Khan N, Bhat R, Patel AK, et al. Discovery of small molecule inhibitors of chikungunya virus proteins (nsP2 and E1) using in silico approaches. J Biomol Struct Dyn. 2020;1–25.DOI: 10.1080/07391102.2020.1731602
   Web of Science ®Google Scholar
• Jain J, Kumari A, Somvanshi P, et al. In silico analysis of natural compounds targeting structural and nonstructural proteins of chikungunya virus. F1000Res. 2017;6:1601.
   PubMedGoogle Scholar
• M-J -P-P, Delang L, Ng LFP, et al. virus drug discovery: still a long way to go? Expert Opin Drug Discov. 2019;14(9):855–866.
   PubMed Web of Science ®Google Scholar
• Karlas A, Berre S, Couderc T, et al. A human genome-wide loss-of-function screen identifies effective chikungunya antiviral drugs. Nat Commun. 2016;7:11320.
   PubMed Web of Science ®Google Scholar
• Agarwal G, Gupta S, Gabrani R, et al. Virtual screening of inhibitors against envelope glycoprotein of chikungunya virus: A drug repositioning approach. Bioinformation. 2019;15(6):439–447.
   PubMed Web of Science ®Google Scholar
• Aggarwal M, Kaur R, Saha A, et al. Evaluation of antiviral activity of piperazine against chikungunya virus targeting hydrophobic pocket of alphavirus capsid protein. Antiviral Res. 2017;146:102–111.
   PubMed Web of Science ®Google Scholar
• Abdelnabi R, Neyts J, Delang L. Towards antivirals against chikungunya virus. Antivir Res. 2015;121:59–68.
   PubMed Web of Science ®Google Scholar
• Ferreira AC, Reis PA, de Freitas CS, et al. Beyond members of the flaviviridae family, sofosbuvir also inhibits chikungunya virus replication. Antimicrob Agents Chemother. 2019;63(2):e01389–18.
   PubMed Web of Science ®Google Scholar
• Bhat SM, Mudgal PP, Sudheesh N, et al. Spectrum of candidate molecules against Chikungunya virus - an insight into the antiviral screening platforms. Expert Rev Anti Infect Ther. 2019;17(4):243–264.
   PubMed Web of Science ®Google Scholar
• Sharma A, Bhomia M, Yeh T-J, et al. Miltefosine inhibits Chikungunya virus replication in human primary dermal fibroblasts. F1000Research. 2018;7:9.
   PubMedGoogle Scholar
• Kumar P, Kumar D, Giri R. Targeting the nsp2 cysteine protease of chikungunya virus using FDA approved library and selected cysteine protease inhibitors. Pathogens. 2019;8(3):128.
   PubMed Web of Science ®Google Scholar
• Emory University. Nucleotide and nucleoside therapeutic compositions and uses related thereto. US10149859; 2018.
   Google Scholar
• Aravive Biologics, Inc. Antiviral activity of Gas6 inhibitor. US10137173; 2018
   Google Scholar
• Alleron Therapeutics, Inc. Peptidomimetic macrocycles. US10022422; 2018.
   Google Scholar
• 3-V Biosciences, Inc. Heterocyclic modulators of lipid synthesis for use against cancer and viral infections. US9994550 ;2018.
   Google Scholar
• F. Hoffmann-La Roche AG. Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease. US9988390; 2018.
   Google Scholar
• Kineta, Inc. Anti-viral compounds. pharmaceutical compositions, and methods of use thereof. US9884876; 2018.
   Google Scholar
• The Trustees of Princeton University. Treatment of viral infections by modulation of host cell metabolic pathways. US9757407; 2017.
   Google Scholar
• Emory University. Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections. US9662332; 2017.
   Google Scholar
• Sarepta Therapeutics Inc. Antisense modulation of interleukins 17 and 23 signaling. US9238042; 2016.
   Google Scholar
• Chung yuan christian university, national defensive medical center. Method for treating Chikungunya Virus Infection. US9381175. 2016.
   Google Scholar
• Pop Test Oncology LLC. Pharmaceutical compositions and methods. US10238666; 2019.
   Google Scholar
• Tamir Biotechnology, INC. Methods of treating and prophylactically protecting mammalian patients infected by viruses classified in baltimore group. US9919034;2018.
   Google Scholar
• Stamets, Edward P. Antiviral activity from medicinal mushrooms and their active constituents. US9931316; 2018.
   Google Scholar
• Griffith University. Treatment of alphavirus-induced inflammation. US20190255097; 2019
   Google Scholar
• Fox JM, Diamond MS. Immune-mediated protection and pathogenesis of chikungunya virus. J Immunol. 2016;197(11):4210–4218.
   PubMed Web of Science ®Google Scholar
• Broeckel R, Fox JM, Haese N, et al. Therapeutic administration of a recombinant human monoclonal antibody reduces the severity of chikungunya virus disease in rhesus macaques. PLoS Negl Trop Dis. 2017;11(6):e0005637.
   PubMed Web of Science ®Google Scholar
• Kam Y-W, Lee WWL, Simarmata D, et al. Longitudinal analysis of the human antibody response to chikungunya virus infection: Implications for serodiagnosis and vaccine development. J Virol. 2012;86(23):13005–13015.
   PubMed Web of Science ®Google Scholar
• Jin J, Galaz-Montoya JG, Sherman MB, et al. Neutralizing Antibodies Inhibit Chikungunya Virus Budding at the Plasma Membrane. Cell Host Microbe. 2018;24(3):417–428.e5.
   PubMed Web of Science ®Google Scholar
• Quiroz JA, Malonis RJ, Thackray LB, et al., Human monoclonal antibodies against chikungunya virus target multiple distinct epitopes in the E1 and E2 glycoproteins. PLoS Pathog. 2019;15(11): e1008061.
   PubMed Web of Science ®Google Scholar
• Kim J, Yang J, Kim YB, et al. Development of a specific CHIKV-E2 monoclonal antibody for chikungunya diagnosis. Virol Sin. 2019;34(5):563–571.
   PubMed Web of Science ®Google Scholar
• Tuekprakhon A, Puiprom O, Sasaki T, et al., Broad-spectrum monoclonal antibodies against chikungunya virus structural proteins: promising candidates for antibody-based rapid diagnostic test development. PLoS One. 2018;13(12): e0208851.
   PubMed Web of Science ®Google Scholar
• Warter L, Lee CY, Thiagarajan R, et al. Chikungunya virus envelope-specific human monoclonal antibodies with broad neutralization Potency. J Immunol. 2011;186(5):3258–3264.
   PubMed Web of Science ®Google Scholar
• Fric J, Bertin-Maghit S, Wang CI, et al. Use of human monoclonal antibodies to treat Chikungunya virus infection. J Infect Dis. 2013;207(2):319–322.
   PubMed Web of Science ®Google Scholar
• Pal P, Dowd KA, Brien JD, et al. Development of a highly protective combination monoclonal antibody therapy against Chikungunya virus. PLoS Pathog. 2013;9(4):e1003312.
   PubMed Web of Science ®Google Scholar
• International business machines corporation; agency for science, technology and research; national university of Singapore. Cationic polyamines for treatment of viruses. US 9682100; 2017.
   Google Scholar
• Pal P, Fox JM, Hawman DW, et al. Chikungunya viruses that escape monoclonal antibody therapy are clinically attenuated, stable, and not purified in mosquitoes. J Virol. 2014;88(15):8213–8226.
   PubMed Web of Science ®Google Scholar
• Fox JM, Roy V, Gunn BM, et al. Optimal therapeutic activity of monoclonal antibodies against chikungunya virus requires Fc-FcR interaction on monocytes. Sci Immunol. 2019;4(32):eaav5062.
   PubMed Web of Science ®Google Scholar
• Kose N, Fox JM, Sapparapu G, et al. A lipid-encapsulated mRNA encoding a potently neutralizing human monoclonal antibody protects against Chikungunya infection. Sci Immunol. 2019;4(35):eaaw6647.
   PubMed Web of Science ®Google Scholar
• Hurtado J, Acharya D, Lai H, et al. In vitro and in vivo efficacy of anti-chikungunya virus monoclonal antibodies produced in wild-type and glycoengineered Nicotiana benthamiana plants. Plant Biotechnol J. 2020;18(1):266–273.
   PubMedGoogle Scholar
• Agency for Science Technology Research. Binding molecules against Chikungunya virus and uses thereof. US9738704; 2017.
   Google Scholar
• Institute Pasteur. Anti-chikungunya monoclonal antibodies and uses thereof. US8449887; 2013
   Google Scholar
• Inovio Pharmaceuticals, INC. DNA antibody constructs and method of using same. US10087240; 2018.
   Google Scholar
• Agenus INC.; Ludwig institute for cancer research ltd; Memorial sloan kettering cancer center. Anti-CTLA-4 antibodies and methods of use thereof. US10144779; 2018.
   Google Scholar
• Cimica V, Galarza JM. Adjuvant formulations for virus-like particle (VLP) based vaccines. Clin Immunol. 2017;183:99–108.
   PubMed Web of Science ®Google Scholar
• Abeyratne E, Freitas JR, Zaid A, et al., Attenuation and stability of chikv-nols, a live-attenuated chikungunya virus vaccine candidate. Vaccines (Basel). 2018;7(1): 2.
   Web of Science ®Google Scholar
• Goyal M, Chauhan A, Goyal V, et al. Recent development in the strategies projected for chikungunya vaccine in humans. Drug Des Devel Ther. 2018;12:4195–4206.
   PubMed Web of Science ®Google Scholar
• Chang L-J, Dowd KA, Mendoza FH, et al. Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trial. Lancet. 2014;384(9959):2046–2052.
   PubMed Web of Science ®Google Scholar
• Reisinger EC, Tschismarov R, Beubler E, et al., Immunogenicity, safety, and tolerability of the measles-vectored chikungunya virus vaccine MV-CHIK: a double-blind, randomised, placebo-controlled and active-controlled phase 2 trial. Lancet. 2018;392(10165): 2718–2727.
   PubMed Web of Science ®Google Scholar
• Erasmus JH, Seymour RL, Kaelber JT, et al. Novel insect-specific eilat virus-based chimeric vaccine candidates provide durable, mono-and multivalent, single-dose protection against lethal alphavirus challenge. J Virol. 2018;92(4):e01274–17.
   PubMed Web of Science ®Google Scholar
• Modernatx Inc. Chikungunya virus RNA vaccines. US20190008947; 2019.
   Google Scholar
• United States, As represented by the secretary of the army, fort detrick. inactived vaccine for chikungunya virus. US20190054161; 2019.
   Google Scholar
• Medigen, INC., Frederick. Infectious DNA Vaccines Against Chikungunya Virus. US9694065; 2017.
   Google Scholar
• Institute Pasteur; Themis bioscience GMBH; Centre National; De La recherche scientifioue. recombinant measles virus expressing chikungunya virus polypeptides and their applications. US9655961; 2017.
   Google Scholar
• The United States of America, as represented by the secretary, department of health and human services. Virus-Like Particles (Vlps) Prepared From Chikungunya Virus Structural Proteins. US9353353; 2016.
   Google Scholar
• Bharat Biotech International Limited. Vaccine for Chikungunya virus Infection. US8865184; 2014.
   Google Scholar
• The Board of Regents of the University of Texas System. Chimeric Chikungunya virus and uses thereof. US8343506; 2013.
   Google Scholar
• ModernaTX, Inc. Nucleic acid vaccines. US9872900;2018.
   Google Scholar
• Parashar D, Cherian S. RNAi agents as chikungunya virus therapeutics. Future Virol. 2016;11(5):321–329.
   Web of Science ®Google Scholar
• Gottumukkala SNVS, Dwarakanath CD, Sudarsan S. Ribonucleic acid interference induced gene knockdown. J Indian Soc Periodontol. 2013;17(4):417–422.
   PubMedGoogle Scholar
• Maillard PV, Veen AG, Poirier EZ, et al. Slicing and dicing viruses: antiviral RNA interference in mammals. Embo J. 2019;38(8):e100941.
   PubMed Web of Science ®Google Scholar
• Parashar D, Cherian S. Antiviral perspectives for chikungunya virus. BioMed Res Int. 2014;2014:631642. https://doi.org/10.1155/2014/631642
   PubMed Web of Science ®Google Scholar
• Parashar D, Paingankar MS, Kumar S, et al. Administration of E2 and NS1 siRNAs inhibit chikungunya virus replication in vitro and protects mice infected with the virus. PLoS Negl Trop Dis. 2013;7:9.
   Web of Science ®Google Scholar
• Lam S, Chen KC, Ng MML, et al. Expression of plasmid-based shRNA against the E1 and nsP1 genes effectively silenced chikungunya virus replication. PLoS One. 2012;7:10.
   Web of Science ®Google Scholar
• Indian Council of Medical Research. RNAi agent for inhibition of chikungunya virus. US9574195; 2017.
   Google Scholar
• Nanosur LLC. Post-transcriptionally chemically modified double strand RNAs. US10131911; 2018.
   Google Scholar
• Biomics Biotechnologies Co Ltd. Application of highly conserved domain sequences from viral genome as template to design therapeutic slirnas. US9284560; 2012.
   Google Scholar